1. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
- Author
-
Ren J, Huang Z, Tian J, Li Z, Shen S, Yan H, Wang N, Hu J, Ma X, Ma Z, Liu J, Lu Y, and Sun X
- Subjects
- Child, Female, Humans, Male, China epidemiology, Diphtheria-Tetanus-acellular Pertussis Vaccines economics, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Markov Chains, Pertussis Vaccine economics, Pertussis Vaccine administration & dosage, Pertussis Vaccine immunology, Vaccination economics, Vaccination methods, Cost-Effectiveness Analysis, Immunization, Secondary economics, Quality-Adjusted Life Years, Whooping Cough prevention & control, Whooping Cough economics
- Abstract
Background: In recent years, notified pertussis cases have been increasingly documented in China. It raised a new public health concern of potential optimization in immunization strategy. This study was aimed to determine the cost-effectiveness of different immunization strategies against pertussis-containing vaccines for 6-year-old pre-school children in Shanghai., Methods: A Markov-decision tree model was applied to evaluate two pertussis immunization strategies for 6-year-old pre-school children as following: (1) 1 dose of acellular pertussis (aP) contained vaccine (DTaP or Tdap) booster vaccinated at 6 years of age, and (2) no booster at 6 years of age regimen. Primary outcomes included quality-adjusted life years (QALYs), costs, and incremental cost-utility ratios (ICUR). Sensitivity analyses were performed. The analysis was conducted over a study period of 14 years from a societal perspective., Results: Compared to no booster immunization strategy, administering 1 dose of acellular pertussis (aP) contained vaccine (DTaP or Tdap) booster at 6 years of age, resulted in an average cost reduction of CNY 814.16 (USD 116) per individual, an increase in QALYs by 0.00066, and a rise in per capita net monetary benefit (NMB) by CNY 933.51 (USD 132). The total costs over the study period were reduced by CNY 160.59 million (USD 23 million), utility increased by 130.49 QALYs, and NMB increased by CNY 184.14 million (USD 26 million)., Conclusions: Implementing acellular pertussis booster immunization for 6-year-old pre-school children in Shanghai emerges as a cost-saving immunization strategy, with both cost savings and utility gains., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF